Oncotarget, Vol. 7, No. 41

www.impactjournals.com/oncotarget/

Research Paper

Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer Taketo Nishikawaji1, Yoshimitsu Akiyama1, Shu Shimada1, Kazuyuki Kojima2, Tatsuyuki Kawano3, Yoshinobu Eishi4, Yasuhito Yuasa1, Shinji Tanaka1 1

Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

2

Department of Surgical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

3

Department of Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

4

Department of Human Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Correspondence to: Shinji Tanaka, email: [email protected] Yoshimitsu Akiyama, email: [email protected] Keywords: gastric cancer, histone methyltransferase, H3K9me3, SETDB2 Received: March 18, 2016     Accepted: August 11, 2016     Published: August 26, 2016

ABSTRACT SETDB2 is a histone H3 lysine 9 (H3K9) tri-methyltransferase that is involved in transcriptional gene silencing. Since it is still unknown whether SETDB2 is linked to carcinogenesis, we studied alterations and functions of SETDB2 in human gastric cancers (GCs). SETDB2 protein was highly expressed in 30 of 72 (41.7%) primary GC tissues compared with their normal counterparts by immunohistochemistry. SETDB2 overexpression was significantly associated with the late stage of GCs (P

Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer.

SETDB2 is a histone H3 lysine 9 (H3K9) tri-methyltransferase that is involved in transcriptional gene silencing. Since it is still unknown whether SET...
11MB Sizes 0 Downloads 7 Views